An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment.

drug protocol number
CABL001A2001B
drug sponsor
Novartis
drug study
ABL001 (Asciminib), Imatinib, Nilotinib, Bosutinib
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase